Evidence map›Paper›PMID 28894582›Full record

ArticleMolecular and clinical oncology2017

Prediction model and treatment of high-output ileostomy in colorectal cancer surgery.

Shiki Fujino, Norikatsu Miyoshi, Masayuki Ohue, Yuske Takahashi, Masayoshi Yasui, Keijiro Sugimura, Hirohumi Akita, Hidenori Takahashi, Shogo Kobayashi, Masahiko Yano and 1 more

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06917963 (Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06917963 narecruitingnot on this mapstarted 2025, after this paper: background citation

Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1: a Randomized, Non-blinded, Controlled Trial

TypeinterventionalSponsorMedical University of GdanskRan2025 to 2027Enrolled80ConditionsStoma - Ileostomy, High Output Stoma, Colon Cancer, IBD (Inflammatory Bowel Disease)ArmsIntensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM), Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. How to manage a high-output stoma.Frontline gastroenterology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shiki FujinoDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Norikatsu MiyoshiDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Masayuki OhueDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Yuske TakahashiDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Masayoshi YasuiDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Keijiro SugimuraDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hirohumi AkitaDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Hidenori TakahashiDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Shogo KobayashiDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Masahiko YanoDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Masato SakonDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Osaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to examine the risk factors of high-output ileostomy (HOI), which is associated with electrolyte abnormalities and/or stoma complications, and to create a prediction model. The medical records of 68 patients who underwent colorectal cancer surgery with ileostomy between 2011 and 2016 were retrospectively investigated. All the patients underwent surgical resection for colorectal cancer at the Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan). A total of 7 patients with inadequate data on ileostomy output were excluded. Using a group of 50 patients who underwent surgery between 2011 and 2013, the risk of HOI was classified by a decision tree model using a partition platform. The HOI prediction model was validated in an additional group of 11 patients who underwent surgery between 2014 and 2016. Univariate analysis of clinical factors demonstrated that young age (P=0.003) and high white blood cell (WBC) count (P<0.001) after surgery were significantly correlated with HOI. Operative factors, such as surgical procedure, approach, operative time and blood loss, were not significantly correlated with HOI. Using these clinical factors, the risk of HOI was classified by statistical partition. In this model, three factors (gender, age and WBC on postoperative day 1) were generated for the prediction of HOI. The patients were classified into five groups, and HOI was observed in 0-88% of patients in each group. The area under the curve (AUC) was 0.838. The model was validated by an external dataset in an independent patient group, for which the AUC was 0.792. In conclusion, HOI patients were classified and an HOI prediction model was developed that may help clinicians in postoperative care.

Indexed as

colorectal cancereicosapentaenoic acidhigh-output ileostomyileostomyomega-3 fatty acidpartitionprediction model

Identifiers

PMID28894582
PMCPMC5582453
OpenAlexW2738808540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.